Need to find a common ground with Moderna and Johnson & Johnson for initiating vaccine supply : V K Paul

Discussions are still going on with Moderna and Johnson & Johnson vaccine manufacturers to start their vaccine supplies, though the government has given Emergency Use Authorisation (EUA) for these COVID-19 vaccines, said Dr Vinod K Paul, member of NITI Aayog.

It may be noted that the foreign vaccine manufacturers including Pfizer and Moderna have been seeking indemnity against any legal issues if the vaccine may create any serious adverse reactions.

Apprising the same in a weekly press briefing on COVID-19 developments in the country, Paul informed that the option for using EUA is open for both the companies. “With regard to their import or deployment from the production of Johnson and Johnson in the country, we have been informing you that there are issues around which we still have to find a common ground with respective vaccine manufacturers and we are working in that direction.”

Commenting on the vaccine administration in children, Paul said that Zydus Cadila’s vaccine has been approved for potential use in children.

“We have information on the stock pile and our scientific bodies are discussing how and when and where to. Covaxin trial is very close to completion of trials for children. Once we have results, that vaccine will be potentially available. Biological E has also been granted permission to complete the trial,” he said.

Health Secretary, Rajesh Bhushan, Ministry of Health and Family Welfare, said, “We are still witnessing the second surge. It is not over. Public health response should be on the basis that the second surge is not over though the cases are coming down.”

He urged the public to be careful while celebrating the upcoming festivals in the wake of the pandemic.

  • Related Posts

    Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

    Fujifilm India, a leading healthcare technology company, has expanded its ELUXEO 8000 endoscopy portfolio with the launch of its next-generation therapeutic gastroscopes at Endocon 2026. India is witnessing a growing…

    Draft bill proposes powers for DIs to inspect online pharmacy office premises

    Amidst years of uncertainty over the regulation of e-pharmacies in the country, the draft Drugs, Medical Devices and Cosmetics Bill, 2026, proposes to bestow the powers with the drugs inspectors…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

    Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

    Draft bill proposes powers for DIs to inspect online pharmacy office premises

    Draft bill proposes powers for DIs to inspect online pharmacy office premises

    Argentina committed to reducing barriers to facilitate entry of Indian pharma sector: Government

    Argentina committed to reducing barriers to facilitate entry of Indian pharma sector: Government

    FDA cancels drug sale licences of Cipla Pharma & Life Sciences’ Pune Carry and Forwarding unit

    FDA cancels drug sale licences of Cipla Pharma & Life Sciences’ Pune Carry and Forwarding unit

    Delhi DCA mandates digital tracking for controlled substances on new DMS portal

    Delhi DCA mandates digital tracking for controlled substances on new DMS portal

    How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?

    How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?